Capricor Therapeutics (NASDAQ:CAPR) Downgraded to “Neutral” Rating by Roth Capital

Roth Capital cut shares of Capricor Therapeutics (NASDAQ:CAPR) from a buy rating to a neutral rating in a report issued on Monday, Marketbeat reports. Roth Capital currently has $7.00 price objective on the biotechnology company’s stock.

CAPR has been the topic of several other research reports. B. Riley Financial reaffirmed a “neutral” rating and set a $10.00 price objective on shares of Capricor Therapeutics in a research report on Monday. Oppenheimer restated an “outperform” rating on shares of Capricor Therapeutics in a research note on Monday. LADENBURG THALM/SH SH upgraded shares of Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $44.33.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $6.99 on Monday. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37. The firm has a market cap of $404.79 million, a PE ratio of -3.01 and a beta of 0.42. The firm’s 50 day moving average price is $24.87 and its two-hundred day moving average price is $27.34.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Equities analysts anticipate that Capricor Therapeutics will post -0.49 EPS for the current fiscal year.

Insider Activity at Capricor Therapeutics

In related news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares in the company, valued at $340,954.74. This represents a 68.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 50,000 shares of company stock worth $1,551,658 in the last quarter. 9.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its position in shares of Capricor Therapeutics by 12.4% during the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 557 shares in the last quarter. KBC Group NV acquired a new stake in shares of Capricor Therapeutics in the first quarter valued at approximately $44,000. ACT Capital Management LLC bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $43,000. Nuveen LLC raised its position in Capricor Therapeutics by 2.1% in the 4th quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after purchasing an additional 1,878 shares during the last quarter. Finally, State of Wyoming lifted its holdings in Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after buying an additional 1,913 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor defended deramiocel. The company said it remains engaged with the FDA and plans to address the briefing materials at the advisory committee meeting, preserving a potential opportunity to support the therapy’s benefit-risk profile. Capricor comments on FDA briefing materials
• Positive Sentiment: B. Riley maintained a neutral rating but set a $10 price target, implying substantial potential recovery if Capricor can resolve the FDA’s efficacy concerns. This is a valuation view rather than a new business catalyst.
• Neutral Sentiment: The July 29 FDA advisory committee meeting is the next major catalyst. The panel’s recommendation will influence expectations for the August 22 regulatory decision, although advisory committee votes are not binding.
• Negative Sentiment: FDA reviewers challenged the core approval case for deramiocel, citing concerns over the Phase 3 evidence and whether the treatment demonstrated effectiveness. The development raises the risk of a negative advisory committee outcome, additional regulatory requests, delayed approval, or rejection. Reuters FDA report
• Negative Sentiment: Roth Capital downgraded Capricor from Buy to Neutral and assigned a $7 price target, signaling sharply reduced confidence and limited near-term upside.
• Negative Sentiment: Several law firms announced securities-fraud investigations into whether Capricor or its executives misrepresented or failed to disclose material information about deramiocel’s clinical data. These announcements may add litigation and reputational risk, though they do not establish wrongdoing. Securities fraud investigation announcement

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.